ArticleMikrochimica acta2026
Magnetic core-satellite SERS biosensor for ultrasensitive quantification of squamous cell carcinoma antigen in human serum.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Squamous cell carcinoma antigen (SCCA) a magnetic enrichment-assisted core-satellite surface-enhanced Raman scattering (SERS) biosensor for ultrasensitive squamous cell carcinoma antigen (SCCA) detection is reported. Magnetic nanoparticles functionalized with SCCA capture antibodies act as enrichment cores, while 4-mercaptobenzoic acid (MBA)-encoded Au@Ag core-shell nanoparticles conjugated with SCCA detection antibodies serve as SERS satellites. Target-mediated sandwich immunorecognition induces a dynamically assembled core-satellite structure, bringing plasmonic nanogaps into close proximity and generating reproducible electromagnetic hot spots for signal amplification. Magnetic pre-enrichment and controlled assembly help reduce nonspecific protein interference in serum and contribute to stable signal generation. The biosensor exhibited a monotonic concentration-dependent Raman response over the range of 1 fg/mL to 10¹¹ fg/mL and achieved a limit of detection (LOD) of 60.0 fg/mL. Quantitative determination of serum samples was performed using an independently established matrix-matched calibration curve. The platform was further validated using real human serum samples from early-stage lung SqCC patients (n = 8) and healthy controls (n = 8), showing higher SCCA concentrations in patient samples than in healthy controls and clear discrimination between the two groups. Overall, the proposed magnetic enrichment-assisted core-satellite SERS immunoassay provides a robust analytical strategy for sensitive SCCA quantification in complex serum matrices.
Indexed as
Identifiers
42581181What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.